LDLara Danziger-Isakov

Lara Danziger-Isakov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lara Danziger-Isakov has a total of 914 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Transparency and Continuity in Organ Safety and Vigilance: Concerns Regarding the Transition from DTAC to TRACE

    by Michael G. Ison, Emily Blumberg, Michael Green, Dan Kaul, Cameron R. Wolfe, Marian G. Michaels, Ricardo M. La Hoz, Lara Danziger-Isakov

  • Open Access

    Understanding the Immune Response Changes to Clinical Interventions for Epstein–Barr Virus Infection Prior to Lymphoma Development in Children After Organ Transplants ( UNEARTH )

    by Vikas R. Dharnidharka, Claire Bocchini, Swati Choudhry, Elizabeth Moulton, Lujain Jaza, Joseph Dumayas, Camila Macedo, Elizabeth Zaragoza, Maryam Mysorewala, Michelle Becker‐Hapak, et al.

    Background: Post‐transplant lymphoproliferative disorders (PTLD) remain a major complication of solid organ transplants (SOT), occurring in 1%–10% of patients, but in greater proportions in children. About 50%–80% of cases are Epstein–Barr Virus (EBV) associated, through partially known and still unknown mechanisms. Even in EBV seronaive SOT recipients, transplant of an SOT from an EBV seropositive donor does not always lead to peripheral blood EBV replication. Longitudinal peripheral blood EBV DNA nucleic acid testing (NAT) after SOT has not improved the individual prediction of PTLD occurrence, likely due to variable SOT recipient immune responses. Methods: This prospective study is designed to assess longitudinal and comprehensive T and NK cell phenotyping and responses to peripheral blood EBV replication via multispectral flow cytometry and other assays. We will also compare local to central EBV NAT values and test whether torquetenovirus NAT can act as a simpler assay to predict EBV clearance. We will collect 1390 blood samples across 5 time points in the first year after 347 enrolled (278 completed) SOTs (kidney, liver, heart, lung or intestine) from three major pediatric SOT centers in the U.S.A. Results: As of June 30, 2025, our study has enrolled 133 participants, of whom 110 have received an organ transplant (27% Hispanic ethnicity, 16% black race, median age 8 years, across all 4 major SOT types). Conclusions: By study end, we will know the global immune responses to EBV replication across a spectrum of clinical pediatric SOT situations. We expect to find key immune mechanisms that will predict poor or delayed EBV clearance despite clinical interventions. These findings may lead to new translational immunotherapy approaches to treat EBV DNaemia or prevent PTLD. We expect that our findings will also inform EBV oncogenesis in other immunocompromised or immunocompetent populations.


  • Open Access

    Mind the Gap: Disparities in Education on Organ Donation and Transplantation—Results of a Global Survey

    by Andrea Herrera-Gayol, Medhat Askar, Hari S. Meshram, Gabriel E. Gondolesi, Nithya Krishnan, Karen M. Dwyer, Kumud Dhital, Stephen Beed, Peter Stock, Vivek B. Kute, et al.

    Background.: Widely accessible education on organ donation and transplantation (ODT) is a tool to reduce waiting lists, as <10% of transplant needs are met (Global Observatory on Donation and Transplantation). We aimed to assess the current state of access to education on ODT worldwide. Methods.: We surveyed transplant physicians and surgeons worldwide. Respondents were classified according to the mean deceased donation (DD) rate per million population (PMP) of their countries from 2016 to 2021 (excluding 2020): Group (G) 1 (G1) no DD reported, or no data provided to Global Observatory on Donation and Transplantation; (G2) <10 DD PMP; (G3) 10–19.9; (G4) 20–29.9; and (G5) ≥30. We inquired about the availability of education on ODT in countries and regions. Results.: We analyzed 311 respondents. We observed that the availability of education on ODT was as follows: in postgraduate education (77.2% in countries, 70.4% in regions), in undergraduate medical school (52.8%, 50.6%), in elementary school (14.2%, 14.2%), in high school (24.6%, 25.7%), and for the public (58.8%, 57.2%). The highest challenges were observed mainly in countries with lower DD rates. Conclusions.: This worldwide survey suggests that there are areas for improvement at a global level in education on ODT, spanning from schoolchildren to the public and from undergraduate to postgraduate medical students. This is a “Call to Action” to close the global education gap.

  • Open Access

    System-level Barriers Reducing Access to Transplantation: Results of a Global Survey

    by Andrea Herrera-Gayol, Medhat Askar, Hari S. Meshram, Gabriel E. Gondolesi, Nithya Krishnan, Karen M. Dwyer, Kumud Dhital, Stephen Beed, Peter Stock, Vivek B. Kute, et al.

    Background.: Global organ shortage is well documented; yet systemic barriers constraining access to transplantation remain poorly defined. Our study aimed to identify and map these barriers. Methods.: A web-based survey was conducted from May 2022 to March 2023 among physicians and surgeons involved in organ donation and transplantation (ODT) from transplantation societies worldwide: (1) Hospital structure, legislation and policies, and financial barriers, addressed to program directors; (2) Questions on education on ODT directed to all participants, and questions about donor acceptance for transplant specialists; (3) Questions on donor identification for critical care specialists and questions about organ acceptance directed to transplant specialists; (4) Demographic questions for everyone. Respondents were grouped according to the mean deceased donation (DD) rate per million population from years 2016 to 2019 and 2021: Group (G) 1 (G1) No DD reported, or no data provided to global observatory on donation and transplantation; (G2) <10 DD per million population; (G3) 10–19.9; (G4) 20–29.9; (G5) ≥30. Results.: We present answers from program directors. There were 150 program directors from 438 respondents. Financial barriers ranked highest, negatively affecting access to transplantation worldwide. G1 indicated the highest percentage of challenges. Those from G4 and G5 provided the least amount of challenges; however, training programs remain areas for improvement. Responses from G2 and G3 were similar, positioned between those from G1, and G4 and G5. Conclusions.: The organ shortage emergency is exacerbated by parallel system-level deficiencies. This global survey identifies specific, actionable deficits that must be addressed to build equitable transplant systems worldwide.

  • Open Access

    Acceptance of Organs From Deceased Donors: Results of a Global Survey

    by Marcelo Cantarovich, Medhat Askar, Shaifali Sandal, Hari S. Meshram, Stephen Beed, Karen M. Dwyer, Nithya Krishnan, Mohammad Ghnaimat, Vivek B. Kute, Carlos Diaz, et al.

    Background.: With <10% of transplantation needs being met, one contributing factor may be the potential subjectivity in transplant specialists’ acceptance of organs. Such decisions, if influenced by knowledge and/or comfort gaps, warrant intervention. We assessed knowledge and comfort gaps regarding deceased donation (DD) among critical care specialists and organ acceptance among transplant specialists. Methods.: The Transplantation Society working group surveyed specialists on end-of-life management and organ acceptance. Participants, stratified by country DD rates, ranked their current and desired levels of knowledge or comfort (on a 0–100 scale) for survey questions. The differences between current and desired knowledge and comfort were reported as gaps. Results.: Among 438 responses, the largest global knowledge gaps were for positive serology for Chagas (gap 30), multidrug-resistant bacterial infection (gap 23.5), HIV (gap 20), cancer history <5 y (gap 20), primary brain malignancies (gap 17.5), and high-risk behavior (gap 16). The largest global comfort gaps were for positive serology for Chagas (gap 29.5), multidrug-resistant bacterial infection (gap 21), excessive alcohol use (gap 20), primary brain malignancies (gap 20), and high-risk behavior (gap 16). Relevant knowledge and comfort gaps, both ranging from 10 to 50, were observed in the acceptance of organs from donors after circulatory determination of death. In general, countries with higher DD rates demonstrated smaller knowledge and comfort gaps than countries with lower DD rates. Conclusions.: This survey reveals important knowledge and comfort gaps in DD organ acceptance. Targeted education could increase organ utilization and help address transplantation shortages.


  • Open Access

    Burden and Risk Factors for Severe Respiratory Syncytial Virus Infection among Pediatric Hematopoietic Cell Transplant Recipients

    by Diego R Hijano, Surabhi B Vora, Yilun Sun, Li Tang, Ronald H Dallas, Jose A Ferrolino, Madeline B Johnson, Kim J Allison, Monica Ardura, Emily Ansusinha, et al.

    Background: Respiratory syncytial virus (RSV) causes substantial morbidity in pediatric hematopoietic cell transplant (HCT) recipients; however, risk factors for severe disease remain incompletely characterized. Methods: We conducted a multicenter retrospective cohort study across 16 U.S. transplant centers, evaluating children and adolescents (0–19 years) who underwent HCT and developed a laboratory-confirmed RSV infection between 2010 and 2019. Clinical characteristics, laboratory values, and immunosuppressive and transplant history were analyzed. Outcomes included new or increased supplemental oxygen requirement, RSV-related hospitalization, progression to lower respiratory tract infection (LRTI), invasive mechanical ventilation, and 90-day mortality. Univariate logistic regression was used to screen candidate predictors, followed by the least absolute shrinkage and selection operator for variable selection, and multivariable logistic regression to identify independent predictors associated with clinical outcomes. Results: Among 204 pediatric HCT recipients with RSV infection, 41.7% had RSV-related hospitalization, 21.2% required new or increased supplemental oxygen, and 4% required invasive mechanical ventilation within 28 days after the diagnosis. Mortality within 90 days was 5.4%, with one death attributable to RSV. In multivariable models, female sex, younger age (particularly <5 years), neutropenia (ANC <500/mm3), presence of co-pathogen in the respiratory tract and chronic lung disease were independently associated with this oxygen outcome, while non-peripheral graft sources and T-cell–depleting therapy were associated with RSV-related hospitalization. Conclusions: Severe outcomes are common in pediatric HCT recipients with RSV infection. Younger age, markers of impaired immune recovery, history of chronic lung disease, and T-cell–depleting therapy are major determinants of adverse outcomes. These findings support targeted risk stratification and may inform preventive and treatment strategies in this high-risk population.

  • Vaccination and safe living strategies for solid organ transplant candidates and recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

    by Deepali Kumar, Robin Avery, Lara Danziger-Isakov, Victoria G. Hall, Benjamin Hanisch, Courtney E. Harris, Olivia S. Kates, Hannah H. Nam, Robert J. Rolfe, Camille N. Kotton


  • Open Access

    Incidence and Outcomes of Human Adenovirus Infection and Disease in a Multicenter Cohort of Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

    by Brian T Fisher, Jesse A Blumenstock, Craig L K Boge, Sydney Shuster, Alix E Seif, Michael Green, Marian G Michaels, Jessie L Alexander, Monica I Ardura, Jeffery J Auletta, et al.

    Background: Human adenovirus (HAdV) among pediatric allogeneic hematopoietic cell transplant (allo-HCT) recipients can result in asymptomatic infection with risk for disease progression. There are limited data defining HAdV infection, disease, and case-fatality rates in a HAdV polymerase chain reaction (PCR) surveillance testing era. The current study aimed to define these outcomes using a priori definitions applied by a central review committee. Methods: Pediatric allo-HCT recipients were followed up for 180 days after HCT at 10 pediatric institutions. Blood and stool specimens were collected 0–7 days prior to allo-HCT for serum HAdV immunoglobulin G and stool HAdV PCR testing. Clinical data, including HAdV PCR testing results, informed central review committee–designated outcomes of HAdV infection, including DNAemia, disease, and deaths (case-fatality rate). Outcomes were reported by HAdV surveillance testing status and by pretransplant research specimen results. Results: The cohort included 819 allo-HCT recipients; 649 (79.2%) were under HAdV surveillance. The HAdV infection and DNAemia incidence among surveilled patients was 27.1% and 16.0%, respectively. The incidence of proven or probable HAdV disease was 10.9% for the cohort and, 12.6% for those under surveillance. The HAdV infection incidence was highest (13 of 25 [52.0%]) in patients with pre-HCT HAdV immunoglobulin G and stool PCR positivity. The attributable case-fatality rate for those with proven or probable disease was 13.5%. Conclusions: HAdV infection and disease are common among pediatric allo-HCT recipients. HAdV disease is associated with a substantial HAdV-attributable mortality rate. Clinical trials assessing novel HAdV in pediatric allo-HCT recipients are needed. Pretransplant serology and stool PCR testing could identify high-risk patients for trial enrollment.

  • Open Access

    Prepared or at-risk? Evaluating live viral vaccine coverage and vaccine immunogenicity before pediatric solid organ transplantation

    by Benhur Sirvan Cetin, Caitlin Brammer, William Otto, Kerrigan Perkins, Teresa Ambrosino, Hilary Miller-Handley, Mark Murphy, Grant Paulsen, Emily Cain, Kathleen Campbell, et al.

    Pediatric solid organ transplant recipients are at high risk for complications from vaccine-preventable diseases, yet pre-transplant vaccination coverage is often inconsistent. We conducted a retrospective cohort study of 421 pediatric transplant recipients between 2018 and 2024 to evaluate vaccination status and serologic immunity for varicella and measles at the time of initial evaluation, listing, and transplantation. At the time of transplant, 19.2% of patients for varicella and 21.6% for measles were under-vaccinated, with infants having the highest rates of incomplete vaccination. A portion of patients (7.1% for varicella, 8.6% for measles) transitioned from full to incomplete vaccination status during the pre-transplant period, a change associated with a shorter time from evaluation to listing. Kidney recipients had the highest completed vaccination rates (>94%), whereas rates for liver and heart recipients were substantially lower (58%–72%). Among fully vaccinated patients, seronegativity was observed for varicella (23.6%) and measles (13.0%). In conclusion, many pediatric transplant candidates, particularly infants and those awaiting liver or heart transplant, are incompletely vaccinated. A dynamic change in vaccination status from evaluation to transplant highlights an urgent need for continuous monitoring and improved strategies to protect these vulnerable children.